贝前列素钠联合缬沙坦治疗糖尿病肾病的疗效  

Effect of beprost sodium combined with valsartan on diabetic nephropathy

作　　者：陆伟霞 LU Weixia(Department of General Medicine,Jiangnan Hospital,Guangdong Province,Guangzhou 510300,China)

机构地区：[1]广东江南医院综合内科,广州市510300

出　　处：《临床合理用药杂志》2022年第5期17-19,23,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察贝前列素钠联合缬沙坦治疗糖尿病肾病(DN)的临床疗效及其对血浆血管内皮生长因子(VEGF)和内皮素-1(ET-1)水平的影响。方法选取2018年7月-2020年7月广东江南医院收治的DN患者82例,按随机数字表法分为观察组和对照组各41例。2组均予常规治疗,对照组给予缬沙坦治疗,观察组在对照组治疗的基础上联合贝前列素钠治疗,2组疗程均为12周。比较2组患者临床疗效、治疗前后血糖指标、肾功能指标及血浆VEGF和ET-1水平。结果观察组患者总有效率为85.37%,高于对照组的63.41%(χ^(2)=5.185,P=0.023);治疗12周后,2组患者空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、血肌酐(SCr)、尿素氮(BUN)、24 h尿蛋白及血浆VEGF和ET-1水平均低于治疗前,且观察组低于对照组(P均<0.01)。结论贝前列素钠联合缬沙坦治疗DN疗效好,能改善患者血糖和肾功能指标,下调血浆VEGF和ET-1水平,值得临床推广应用。Objective To observe the clinical efficacy of beprost sodium combined with valsartan in the treatment of diabetic nephropathy( DN) and its effect on plasma levels of vascular endothelial growth factor(VEGF) and endothelin-1(ET-1).Methods 82 DN patients admitted to Jiangnan Hospital in Guangdong Province from July 2018 to July 2020 were selected,and they were divided into observation group and control group according to random number table method,41 cases in each group.Both groups were given conventional treatment,the control group was given valsartan treatment,and the observation group was combined with berprost sodium treatment on the basis of the treatment in the control group,the course of treatment in both groups was 12 weeks.The clinical efficacy,blood glucose indexes,renal function indexes and plasma VEGF and ET-1 levels were compared between 2 groups before and after treatment.Results The total effective rate of observation group was 85.37%,which was higher than that of control group( 63.41%)( χ^(2)= 5.185,P = 0.023).After 12 weeks of treatment,the levels of fasting blood glucose( FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin( HbA1c),serum creatinine( SCr),urea nitrogen( BUN),24 h total urine protein and plasma VEGF and ET-1 in 2 groups were lower than before,and the observation group was lower than the control group( all P < 0.01).Conclusion Beprost sodium combined with valsartan has good efficacy in the treatment of DN,can improve patients’ blood glucose and renal function indexes,and down-regulate plasma VEGF and ET-1 levels,which is worthy of clinical application.

关 键 词：糖尿病肾病 贝前列素钠 缬沙坦 血管内皮生长因子 内皮素-1 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]